Literature DB >> 1413827

Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications.

P E Goretzki1, J Lyons, S Stacy-Phipps, W Rosenau, M Demeure, O H Clark, F McCormick, H D Röher, H R Bourne.   

Abstract

Activating mutations of ras-genes (Kirsten-ras, Harvey-ras, N-ras) and genes encoding for the alpha subunit of G-proteins (Gs, Gi2, Gi3, Go, Gz) were assessed in 32 differentiated thyroid cancer (DTC) tissues from German (n = 22) and American (n = 10) patients. Gs-protein (GSP) and/or ras mutations were found in 69% of all tissues with a heterogeneous distribution pattern. An increased prevalence could be demonstrated in metastatic (8 of 9 mutation positive) when compared to localized disease (13 of 23 mutation positive) (p less than 0.001) and in patients greater than 50 years of age (16 of 18 mutation positive), when compared to younger patients (6 of 14 mutation positive) (p less than 0.001). No activating mutations were found on H-ras and K-ras genes nor on genes encoding for the alpha subunits of Gi2, Gi3, Go, and Gz. Differentiated thyroid cancer tissue from German patients revealed a higher prevalence for GSP mutations (73%) than did DTC from American patients (20%) (p less than 0.001). We demonstrated a high frequency of ras and GSP mutations in DTC and suggest that these mutations may contribute to our basic understanding of this disease and might initiate a new search for more rational and individualized therapeutic approaches in patients with DTC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1413827     DOI: 10.1007/bf02067325

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  39 in total

Review 1.  Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth.

Authors:  H Studer; H J Peter; H Gerber
Journal:  Endocr Rev       Date:  1989-05       Impact factor: 19.871

2.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

3.  Hyperthyroidism and thyroid cancer.

Authors:  C J Edmonds; M Tellez
Journal:  Clin Endocrinol (Oxf)       Date:  1988-02       Impact factor: 3.478

4.  Increased follicular heterogeneity in experimental colloid goiter produced by refeeding iodine excess after thyroid hyperplasia.

Authors:  M C Many; J F Denef; S Hamudi; S Haumont
Journal:  Endocrinology       Date:  1986-02       Impact factor: 4.736

5.  TSH suppression in the management of thyroid nodules and thyroid cancer.

Authors:  O H Clark
Journal:  World J Surg       Date:  1981-01       Impact factor: 3.352

6.  Growth regulation of normal thyroids and thyroid tumors in man.

Authors:  P E Goretzki; A Frilling; D Simon; H D Roeher
Journal:  Recent Results Cancer Res       Date:  1990

7.  Thyrotropin (TSH) stimulates cell growth and DNA synthesis in monolayer cultures of human thyrocytes independent of the adenylate-cyclase system.

Authors:  P E Goretzki; R Koob; C Koller; H D Röher
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1987

8.  Clonal composition of benign and malignant human thyroid tumors.

Authors:  H Namba; K Matsuo; J A Fagin
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

9.  Frequency and morphology of malignant tumours of the thyroid before and after the introduction of iodine-prophylaxis.

Authors:  F Hofstädter
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

10.  Multifactorial study of prognostic factors in differentiated thyroid carcinoma and a re-evaluation of the importance of age.

Authors:  F Bacourt; B Asselain; J C Savoie; E D'Hubert; J P Massin; G Doucet; A Leger; H Garnier
Journal:  Br J Surg       Date:  1986-04       Impact factor: 6.939

View more
  14 in total

Review 1.  Predictors of thyroid tumor aggressiveness.

Authors:  O H Clark
Journal:  West J Med       Date:  1996-09

2.  Distribution of Gs-alpha activating mutations in human thyroid tumors measured by subcloning.

Authors:  V N Gorelov; M Gyenes; F Neser; H D Röher; P E Goretzki
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 3.  Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins.

Authors:  T A Fields; P J Casey
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

4.  Ras mutations are uncommon in sporadic thyroid cancer in children and young adults.

Authors:  C Fenton; J Anderson; Y Lukes; C A Dinauer; R M Tuttle; G L Francis
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

Review 5.  Recurrent thyroid cancer.

Authors:  O H Clark
Journal:  J Endocrinol Invest       Date:  1995-02       Impact factor: 4.256

6.  Overexpression of Gs alpha subunit in thyroid tumors bearing a mutated Gs alpha gene.

Authors:  V N Gorelov; K Dumon; N S Barteneva; D Palm; H D Röher; P E Goretzki
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

8.  Thyroid follicular oncogenesis in iodine-deficient and iodine-sufficient areas: search for alterations of the ras, met and bFGF oncogenes and of the Rb anti-oncogene.

Authors:  L Bartolone; F Vermiglio; M D Finocchiaro; M A Violi; D French; A Pontecorvi; F Trimarchi; S Benvenga
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

9.  [Growth and invasion of differentiated thyroid gland carcinoma: importance of signal transduction].

Authors:  T Hölting; O Y Duh; O H Clark; C Herfarth
Journal:  Langenbecks Arch Chir       Date:  1995

10.  Significance of P53 in human thyroid tumors.

Authors:  D Simon; P E Goretzki; V Gorelev; B Ebling; E Reishaus; J Lyons; H Haubruck; H D Röher
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.